LMWH sensitizes human non-small cell lung carcinomas A549 cells to genifitib through inhibiting DOCK1 expression and AKT activation

Gefitinib is a new molecular targeted antitumor drug and recently used widely in lung cancer treatment in China. But when used for an average ten-month period, patient show resistance to gefitinib and this resistance limit its con- tinued use. Low-molecular-weight heparin （LMWH） has potent inhibitory action on experimental metastasis. In present study, we are trying to find whether LMWH combined with gefitinib could sensitize its antitumor effects and potential relieve its resistance phenomenon in fifo and in vitro. Enoxaparin （one kind of LMWH） combined with gefitinib inhibited the growth of xenografl A549-1uc-C5 tumors in nude mice and reduced lung colony formation compared with gefitinib alone.